BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 28412238)

  • 1. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
    Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
    Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
    Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
    Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
    Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations.
    Tariq M; Alam MA; Singh AT; Iqbal Z; Panda AK; Talegaonkar S
    Colloids Surf B Biointerfaces; 2015 Apr; 128():448-456. PubMed ID: 25769281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
    Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
    Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
    Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
    Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.
    Yazdian-Robati R; Ramezani M; Jalalian SH; Abnous K; Taghdisi SM
    Pharm Res; 2016 Sep; 33(9):2289-97. PubMed ID: 27283831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
    Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
    Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo.
    Jalalian SH; Ramezani M; Abnous K; Taghdisi SM
    Cancer Lett; 2018 Mar; 416():87-93. PubMed ID: 29253524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
    Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
    Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M; Nafee N; Saad H; Kazem A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
    Mosafer J; Teymouri M; Abnous K; Tafaghodi M; Ramezani M
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():123-133. PubMed ID: 28024568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
    Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
    Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells.
    Li L; Xiang D; Shigdar S; Yang W; Li Q; Lin J; Liu K; Duan W
    Int J Nanomedicine; 2014; 9():1083-96. PubMed ID: 24591829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
    Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
    Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
    Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan-Coated Poly(lactic-co-glycolic acid)-Diiodinated boron-Dipyrromethene Nanoparticles Improve Tumor Selectivity and Stealth Properties in Photodynamic Cancer Therapy.
    Voon SH; Tiew SX; Kue CS; Lee HB; Kiew LV; Misran M; Kamkaew A; Burgess K; Chung LY
    J Biomed Nanotechnol; 2016 Jul; 12(7):1431-52. PubMed ID: 29336539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
    Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
    Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.